LunAIRo, Apnimed’s second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea Index (AHI) from baseline at 26 weeks (p<0.001 vs. placebo); no serious adverse events related to AD109 […]
Tag: Apnimed
#Rosal Top Picks
Recent Posts
- NEW YORK, Dec. 11, 2025 /PRNewswire/ — Class
- LAS VEGAS, Dec. 11, 2025 /PRNewswire/ —
- The agency closes its first full year with
- A Bold New Line of Cowgirl Boots Reflecting Reba
- MORRISVILLE, N.C., Dec. 11, 2025 /PRNewswire/
